ZBTB7C Inhibitors
The class of ZBTB7C inhibitors encompasses diverse compounds that modulate the expression and function of ZBTB7C, a transcription factor involved in various cellular processes. JQ1, a BET bromodomain inhibitor, indirectly influences ZBTB7C by disrupting BET protein interactions with acetylated histones, altering chromatin structure and influencing ZBTB7C access to specific genomic loci. This modulation provides insights into the epigenetic regulation of ZBTB7C-mediated processes. Nutlin-3, a MDM2 inhibitor, indirectly affects ZBTB7C by disrupting the MDM2-p53 interaction, altering the stability of p53. This modulation can impact ZBTB7C expression and function by influencing the transcriptional regulation of genes involved in cellular processes influenced by both ZBTB7C and p53. 5-Azacytidine, a DNA methyltransferase inhibitor, indirectly influences ZBTB7C by disrupting DNA methylation patterns, altering epigenetic regulation and impacting the chromatin environment relevant to ZBTB7C-mediated processes.
The diverse set of ZBTB7C inhibitors, including PX-478, SP600125, Ruxolitinib, SB203580, Rapamycin, PD98059, and Y-27632, provides valuable tools for understanding the intricate regulatory networks involving ZBTB7C. These compounds indirectly influence ZBTB7C by disrupting specific signaling pathways, revealing avenues for conditions where ZBTB7C dysregulation plays a role. The nuanced interactions between these inhibitors and ZBTB7C highlight the complex interplay between transcriptional regulation, epigenetic modifications, and cellular signaling pathways. Further exploration of these inhibitors can contribute to a comprehensive understanding of ZBTB7C's role in cellular homeostasis and disease processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor indirectly influencing ZBTB7C. JQ1 disrupts BET protein interactions with acetylated histones, altering chromatin structure. This modulation impacts ZBTB7C expression and function by regulating its access to specific genomic loci. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
MDM2 inhibitor influencing ZBTB7C indirectly. Nutlin-3 disrupts the MDM2-p53 interaction, affecting the stability of p53. This modulation can impact ZBTB7C expression and function by altering the transcriptional regulation of genes involved in cellular processes influenced by both ZBTB7C and p53. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor affecting ZBTB7C indirectly. 5-Azacytidine disrupts DNA methylation patterns, altering epigenetic regulation. This modulation impacts ZBTB7C expression and function by influencing the chromatin environment and accessibility of genomic regions relevant to ZBTB7C-mediated processes. | ||||||
PX-478 | 685898-44-6 | sc-507409 | 10 mg | $175.00 | ||
HIF-1α inhibitor influencing ZBTB7C indirectly. PX-478 disrupts HIF-1α stability, affecting hypoxia-induced signaling pathways. This modulation can impact ZBTB7C expression and function by altering the cellular response to hypoxia, which intersects with ZBTB7C-mediated processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor indirectly affecting ZBTB7C. SP600125 disrupts JNK signaling, altering downstream pathways related to stress responses. This modulation impacts ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by JNK activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor indirectly influencing ZBTB7C. Ruxolitinib disrupts JAK-STAT signaling, altering downstream pathways related to inflammation and immunity. This modulation can impact ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by JAK-STAT activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor indirectly affecting ZBTB7C. SB203580 disrupts p38 MAPK signaling, altering downstream pathways related to stress responses. This modulation impacts ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by p38 MAPK activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor indirectly influencing ZBTB7C. Rapamycin disrupts mTORC1 complex, altering downstream pathways related to cell growth and metabolism. This modulation can impact ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by mTORC1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor indirectly affecting ZBTB7C. PD98059 disrupts the MAPK/ERK pathway, altering downstream signaling cascades. This modulation impacts ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by the MAPK/ERK pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor indirectly influencing ZBTB7C. Y-27632 disrupts ROCK signaling, altering downstream pathways related to cytoskeletal dynamics. This modulation can impact ZBTB7C expression and function by regulating the cellular context in which ZBTB7C participates in processes influenced by ROCK activity. | ||||||